These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16426103)

  • 1. Methodological issues in a comparative study of ziprasidone and risperidone.
    Gharabawi GM; Bossie CA; Mahmoud R; Canuso CM; Lasser RA; Turkoz I; Greenspan A
    J Clin Psychiatry; 2006 Jan; 67(1):162-3; author reply 163-4. PubMed ID: 16426103
    [No Abstract]   [Full Text] [Related]  

  • 2. Methodological concerns in a trial of ziprasidone and olanzapine.
    Ross DE
    Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994735
    [No Abstract]   [Full Text] [Related]  

  • 3. Methodological concerns in a trial of ziprasidone and olanzapine.
    Carnahan RM; Perry PJ
    Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994736
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical experiences and clinical trials.
    Fusar-Poli RR
    CNS Spectr; 2008 Jun; 13(6):461-2; author reply 462-3. PubMed ID: 18567969
    [No Abstract]   [Full Text] [Related]  

  • 5. Priapism associated with two atypical antipsychotic agents.
    Reeves RR; Mack JE
    Pharmacotherapy; 2002 Aug; 22(8):1070-3. PubMed ID: 12173794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone.
    Kuwilsky A; Krumm B; Englisch S; Dressing H; Zink M
    Pharmacopsychiatry; 2010 Aug; 43(6):216-20. PubMed ID: 20589598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
    Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
    J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for successful clinical management of schizophrenia with ziprasidone.
    Fagiolini A; Cañas F; Gallhofer B; Larmo I; Levy P; Montes JM; Papageorgiou G; Zink M; Rossi A
    Expert Opin Pharmacother; 2010 Sep; 11(13):2199-220. PubMed ID: 20658947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.
    Lublin H; Haug HJ; Koponen H; Sigmundsson T; Kolb SA
    World J Biol Psychiatry; 2009; 10(4 Pt 3):710-8. PubMed ID: 18803070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
    Zink M; Kuwilsky A; Krumm B; Dressing H
    J Psychopharmacol; 2009 May; 23(3):305-14. PubMed ID: 18562423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolactin elevation with ziprasidone.
    Lusskin SI; Cancro R; Chuang L; Jacobson J
    Am J Psychiatry; 2004 Oct; 161(10):1925. PubMed ID: 15465997
    [No Abstract]   [Full Text] [Related]  

  • 13. Mania associated with initiation of ziprasidone.
    Nolan BP; Schulte JJ
    J Clin Psychiatry; 2003 Mar; 64(3):336. PubMed ID: 12716277
    [No Abstract]   [Full Text] [Related]  

  • 14. The value of atypical antipsychotics in the treatment of schizophrenia.
    Jessen LM
    Manag Care; 2002 Jul; 11(7 Suppl):8-12; discussion 12-3. PubMed ID: 12181875
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
    Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
    Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperosmolar hyperglycemic state associated with ziprasidone treatment: a case report.
    Létourneau G; Abdel-Baki A; Dubreucq S; Mahone M; Granger B
    J Clin Psychopharmacol; 2011 Oct; 31(5):671-3. PubMed ID: 21881458
    [No Abstract]   [Full Text] [Related]  

  • 17. Risperidone and clozapine for treatment-resistant schizophrenia.
    Meltzer HY
    Am J Psychiatry; 1999 Jul; 156(7):1126-7; author reply 1127-8. PubMed ID: 10401484
    [No Abstract]   [Full Text] [Related]  

  • 18. Ziprasidone augmentation of clozapine in 11 patients.
    Kaye NS
    J Clin Psychiatry; 2003 Feb; 64(2):215-6. PubMed ID: 12633133
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
    Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON
    Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolongation of QTc interval and antipsychotics.
    Taylor DM
    Am J Psychiatry; 2002 Jun; 159(6):1062; author reply 1064. PubMed ID: 12042205
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.